Achieving Self-directed Integrated Cancer Aftercare (ASICA) in Melanoma (ASICA)
Achieving Self-directed Integrated Cancer Aftercare (ASICA) in Melanoma: A Randomized Patient-focused Trial of Delivering the ASICA Intervention as a Means to Earlier Detection of Recurrent and Second Primary Melanoma
Aperçu de l'étude
Statut
Statut
Les conditions
Les conditions
Intervention / Traitement
Intervention / Traitement
Description détaillée
Type d'étude
Type d'étude
Inscription (Réel)
Inscription
Phase
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
-
Aberdeen, Royaume-Uni
- University of Aberdeen
-
Cambridge, Royaume-Uni
- Addenbrookes Hospital
-
-
Critères de participation
Critère d'éligibilité
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Adult (≥18)
- Patients treated for stage 0-2C cutaneous melanoma within the preceding 24 months
Exclusion Criteria:
- Stage 3 and 4 melanoma.
- Previous local recurrence of melanoma within last 24 months.
- Patients who are unable to consent and/or complete questionnaires (e.g. due to cognitive or language issues).
- Patients who are blind or visually impaired.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Diagnostique
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Nombre de bras
Armes et Interventions
Groupe de participants / BrasGroupe de participants / Bras |
Intervention / TraitementIntervention / Traitement |
|---|---|
|
Aucune intervention: Control
Control group will attend their routine melanoma follow-ups
|
|
|
Expérimental: Intervention
The intervention group will use the ASICA app in addition to their routine follow-ups
|
Participants in the intervention arm will be trained to use ASICA (in addition to completing routine follow-up) and participants within the control arm will continue to attend their usual structured melanoma follow-up only.
The hypothesis is that the ASICA intervention will increase TSSE practice in those affected by melanoma without affecting psychological well-being and lead to earlier detection of recurrent and new primary melanoma.
|
Que mesure l'étude ?
Principaux critères de jugement
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
The impact of receiving ASICA on cancer worry
Délai: Up to 12 months following randomisation.
|
This outcome will be measured using Melanoma Worry Scale (MWS).
The scale consists of four questions asking the patients how worried they are about getting melanoma and how this impacts their current lifestyle.
The patients choose the answers on a 5-point scale ranging from 'not at all worried' (best answer) to 'worried almost all the time' (worst answer).
|
Up to 12 months following randomisation.
|
|
The impact of receiving ASICA on anxiety and depression
Délai: Up to 12 months following randomisation.
|
This outcome will be measured using Hospital Anxiety and Depression Scale (HADS).
HADS was devised to measure anxiety and depression in a general medical population of patients.
The questionnaire comprises seven questions for anxiety and seven questions for depression.
The patients choose the answers on a 4-point scale ranging from 'not at all' (best answer) to 'all the time' (worst answer).
Each item on the questionnaire is scored from 0-3 leading to a score range of 0 and 21 for each subscales (anxiety or depression).
For both scales, scores of less than 7 indicate non-cases, scores of 8-10 indicate mild anxiety/depression, scores of 11-14 indicate moderate anxiety/depression, and scores of 15-21 indicate severe anxiety/depression.
|
Up to 12 months following randomisation.
|
|
The impact of receiving ASICA quality of life.
Délai: Up to 12 months following randomisation.
|
This outcome will be measured using EQ-5D-5L questionnaire.
EQ-5D-5L consists of two sections - descriptive system and a visual scale.
The descriptive system comprises of five questions about mobility, self-care, usual activities, pain/discomfort and anxiety/depression.
Each question has five possible answers ranging from: no problems, slight problems, moderate problems, severe problems and extreme problems.
The patient chooses the most appropriate statement in each of the five questions.
This decision results in a 1-digit number that expresses the level selected for that question.
The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state.
The higher the number the worse the health state is.
The visual scale records the patient's self-rated health on a vertical visual analogue scale, where the endpoints are labelled 'The worst health you can imagine' (score of 0) and 'The best health you can imagine' (score of 100).
|
Up to 12 months following randomisation.
|
Mesures de résultats secondaires
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
The impact of receiving ASICA on detection rate of second primary and recurrent melanoma
Délai: Up to 12 months following randomisation.
|
The questionnaire consists of 14 questions asking patients whether they have ever and in the past 12 month checked any part of their skin for signs of skin cancer (yes/no answer).
If so, how often (5 point scale ranging from 'zero' to 'more than six times') and which areas of the body were checked.
The patients are also asked whether they used a mirror or get help to check difficult to reach areas of their body.
The patients are also asked how confident they are about being able to check their own skin.
Patients choose the answers on a 10-point scale ranging from 'not at all confident' (worst answer) to 'highly confident' (best answer).
The final set of questions ask patients whether they have found anything concerning during their last skin check (yes/no answer) and if so what action was taken by the patient (watched it/showed it to a relative/showed it to a professional) and how quickly (immediately, in few days, in a week, in a month, other).
|
Up to 12 months following randomisation.
|
|
The impact of receiving ASICA on adherence to and self-efficacy to conduct TSSE in future
Délai: Up to 12 months following randomisation.
|
This outcome will be measured using a questionnaire designed to determine what the patients think about examining their own skin.
The questionnaire consists of nine statements about how important it is to patients to check their skin, do they do it regularly, does it make them anxious, whether they feel confident about having their skin checked by a professional, and do they make plans regarding when and where they will have their skin checked.
For each statement, patients indicate whether they strongly disagree, disagree, agree, strongly agree, or are unsure.
|
Up to 12 months following randomisation.
|
|
The impact of receiving ASICA on patterns of UK NHS resource use
Délai: Up to 12 months following randomisation.
|
This outcome will be measured using a questionnaire designed to determine whether patients used NHS because of their skin problems.
The set of seven questions is about any appointments within the NHS that patients may have had about their skin in the past 12 months.
Patients are asked whether they had any appointments with a medical professional (GP/nurse/other) for their skin in the past 12 months (yes/no answer), how many (free text) and at what setting (visit at the practice/visit at home/telephone).
Patients are also asked about operations or any other treatment they may have had on their skin in the past 12 months (free text).
Patients are also asked to list any prescribed medicines or non-prescribed skin products in the last 12 months and their cost (free text).
|
Up to 12 months following randomisation.
|
Collaborateurs et enquêteurs
Parrainer
Parrainer
Collaborateurs
Collaborateurs
Les enquêteurs
Les enquêteurs
- Chercheur principal: Peter Murchie, MBChB, PhD, University of Aberdeen
Publications et liens utiles
Publications générales
- Murchie P, Constable L, Hall S, Brant W, Allan J, Johnston M, Masthoff J, Lee A, Treweek S, Ayansina D, Proby C, Rahman K, Walter F, Burrows N, Durrani A, Maclennan G. The Achieving Self-directed Integrated Cancer Aftercare Intervention for Detection of Recurrent and Second Primary Melanoma in Survivors of Melanoma: Pilot Randomized Controlled Trial. JMIR Cancer. 2022 Sep 8;8(3):e37539. doi: 10.2196/37539.
- Allan JL, Johnston DW, Johnston M, Murchie P. Describing, predicting and explaining adherence to total skin self-examination (TSSE) in people with melanoma: a 12-month longitudinal study. BMJ Open. 2022 Aug 30;12(8):e056755. doi: 10.1136/bmjopen-2021-056755.
- Reilly F, Contstable L, Brant W, Rahman K, Durrani A, Burrows N, Proby C, Allan J, Johnston M, Johnston D, Walter F, Murchie P. Achieving integrated self-directed Cancer aftercare (ASICA) for melanoma: how a digital intervention to support total skin self-examination was used by people treated for cutaneous melanoma. BMC Cancer. 2021 Nov 13;21(1):1217. doi: 10.1186/s12885-021-08959-2.
- Murchie P, Masthoff J, Walter FM, Rahman K, Allan JL, Burrows N, Proby C, Lee AJ, Johnston M, Durrani A, Depasquale I, Brant B, Neilson A, Meredith F, Treweek S, Hall S, McDonald A. Achieving Self-Directed Integrated Cancer Aftercare (ASICA) in melanoma: protocol for a randomised patient-focused pilot trial of delivering the ASICA intervention as a means to earlier detection of recurrent and second primary melanoma. Trials. 2019 Jun 3;20(1):318. doi: 10.1186/s13063-019-3453-x.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Début de l'étude
Achèvement primaire (Réel)
Achèvement primaire
Achèvement de l'étude (Réel)
Achèvement de l'étude
Dates d'inscription aux études
Première soumission
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Première publication
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour publiée
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
Autres numéros d'identification d'étude
- 2-028-17
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .